Key result
CAS matches redo-CEA with ~5% restenosis recurrence but avoids higher cranial nerve injury risk.
Why the study?
Restenosis remains the main complication following surgical and endovascular treatment of carotid stenosis.
Carotid restenosis occurs in 6-12% of patients at 2 years post-procedure and requires personalized management based on patient and plaque characteristics.
Comparable restenosis rates favor individualized choice over redo-CEA; leaves open optimal strategy absent randomized data.
Restenosis after carotid endarterectomy and carotid artery stenting remains the main complication after both surgical and endovascular treatment of carotid stenosis, with a 2-year restenosis rate of 6–12%. Complex inflammation processes are the cause of early (<2 years) and late (>2 years) restenosis and principal systemic risk factors are female gender, hypertension, diabetes, dyslipidemia, and smoking. Non-procedural treatment includes lifestyle modifications and best medical therapy. The procedural treatment, considered mostly for symptomatic patients, includes different open and endovascular techniques. The management should be personalized according to patient and plaque characteristics.
No takes yet. Share an insight, caveat, or question.
Bonardelli et al. (2026) conducted a review in Carotid Restenosis. Carotid endarterectomy and carotid artery stenting was evaluated. Restenosis after carotid endarterectomy and carotid artery stenting occurs at a 2-year rate of 6-12% and requires personalized management based on patient and plaque characteristics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: